CPIX
Cumberland Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CPIX
Cumberland Pharmaceuticals Inc.
The largest biopharmaceutical company in the Mid-South
Pharmaceutical
Invalid Date
08/11/2009
NASDAQ Stock Exchange
91
12-31
Common stock
1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203
--
Cumberland Pharmaceuticals Inc., was incorporated in 1999. Focusing on the acquisition, development and commercialization of branded prescription products, it is a growing specialty pharmaceutical company. The company's main target markets are acute care and gastrointestinal diseases in hospitals, which the company believes can effectively penetrate the relatively concentrated physician prescribing base through a relatively small, targeted sales force. The company is committed to providing innovative products that improve the quality of care for patients and address difficult medical requirements. The Company has product development and commercial capabilities and believes it can leverage its existing infrastructure to support its expected growth. The company's management team consists of veterans in the pharmaceutical industry. It has extensive experience in business development, product development, business and finance. The company's business development team identifies, evaluates and negotiates product acquisition, import licensing and export licensing opportunities. The company's product development team develops proprietary product formulations, manages its clinical trials, prepares all regulatory submissions and manages its medical call center. The company's high-quality and professional manufacturers oversee the production of its products. The company's marketing and sales professionals are responsible for its commercial activities, while the company works closely with third-party distribution partners to ensure availability and delivery of its products.
Company Financials
EPS
CPIX has released its 2024 Q4 earnings. EPS was reported at -0.02, versus the expected 0.00, missing expectations. The chart below visualizes how CPIX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CPIX has released its 2024 Q4 earnings report, with revenue of 10.44M, reflecting a YoY change of 11.57%, and net profit of -1.90M, showing a YoY change of 69.82%. The Sankey diagram below clearly presents CPIX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available